Эта статья является препринтом и не была отрецензирована.
О результатах, изложенных в препринтах, не следует сообщать в СМИ как о проверенной информации.
Effective treatment regimen Famotidine with low molecular weight heparin (sodium enoxaparin) severe stages patients COVID-19
2020-06-26
Today, according to the scheme enoxaporin sodium 120 mg per day (160 mg)+ Famotidine 80 mg per day were treated more than 300 people they all have objective evidence of the effectiveness of treatment based on a significant decrease in the blood D-dimer! Using the treatment regimen enoxaparin sodium + Famotidine, it is possible to treat patients with COVID-19 in an outpatient setting and prevent hospitalization in hospitals
Ссылка для цитирования:
Serafimov S. V. 2020. Effective treatment regimen Famotidine with low molecular weight heparin (sodium enoxaparin) severe stages patients COVID-19. PREPRINTS.RU. https://doi.org/10.24108/preprints-3112079
Список литературы
1. Daniel E Freedberg, Joseph Conigliaro, Magdalena E Sobieszczyk, David D Markowitz, Aakriti Gupta, Max R. O'Donnell, Jianhua Li, David A Tuveson, Zhezhen Jin, William C Turner, Donald W Landry, Timothy C Wang, View ORCID ProfileKevin J. Tracey, Michael V Callahan, Julian A Abrams. 2020. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. Medrxiv. doi: https://doi.org/10.1101/2020.05.01.20086694
2. CHEN SHI, CONG WANG, HANXIANG WANG, CHAO YANG, FEI CAI, FANG ZENG, FANG CHENG, YIHUI LIU, TAOTAO ZHOU, BIN DENG, Israel Vlodavsky, JINPING LI, YU ZHANG. 2020. The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study. Medrxiv. doi: https://doi.org/10.1101/2020.03.28.20046144
3. Brendan Borrell. 2020. New York clinical trial quietly tests heartburn remedy against coronavirus. Sciencemag. https://doi:10.1126/science.abc4739
4. Hooman D. Poor , Corey E. Ventetuolo, Thomas Tolbert , Glen Chun, Gregory Serrao , Amanda Zeidman , Neha S. Dangayach , Jeffrey Olin , Roopa Kohli‐Seth , Charles A. Powell. 2020. COVID‐19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. Wiley Online Library. https://doi.org/10.1002/ctm2.44